AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary

AIM ImmunoTech Inc. announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine has been accepted for presentation at the Society for Immunotherapy of Cancer Annual Meeting. The abstract focuses on a Phase 2 trial evaluating the combination of cisplatin, Ampligen, and pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.

OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.

The abstract concerns a Phase 2 single arm efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with AIM’s drug Ampligen and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer. The abstract authors include Robert Edwards, MD, Chief Medical Officer of the UPMC Community and Ambulatory Services Division and Co-Director of the Women’s Cancer Research Center at the UPMC Hillman Cancer Center.

Details for the presentation are as follows:

Abstract Number: 799
Title: Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer

For more information, please visit the SITC website.

About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the company on Twitter, LinkedIn, and Facebook.

FAQ

What is the news about AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. announced the acceptance of an abstract for presentation at the Society for Immunotherapy of Cancer Annual Meeting.

What is the abstract about?

The abstract focuses on a Phase 2 trial evaluating the combination of cisplatin, Ampligen, and pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.

Who are the authors of the abstract?

The abstract authors include Robert Edwards, MD, Chief Medical Officer of the UPMC Community and Ambulatory Services Division and Co-Director of the Women's Cancer Research Center at the UPMC Hillman Cancer Center.

When and where is the Society for Immunotherapy of Cancer Annual Meeting?

The Society for Immunotherapy of Cancer Annual Meeting is being held from November 1 - 5, 2023, in San Diego, CA, and virtually.

Where can I find more information?

For more information, please visit the SITC website.